Uncategorized
Letter re: Statements about Omidria
We agree with Dr. Ferguson (Letter to the Editor, Ocular Surgery News, Feb. 25, 2016) about the importance of controlling surgical costs; however, many of the statements regarding Omidria (phenylephrine/ketorolac 1%/0.3%) in his letter are incorrect. The erroneous statements on pricing and reimbursement were addressed by Dr. Gustafson in his response to Dr. Ferguson’s letter, and other inaccuracies were clarified by Dr. Lindstrom in the editor’s response. We focus here on Dr. Ferguson’s significant misstatements not addressed by Drs. Gustafson or Lindstrom. For each, a factual correction follows. “Preventing intraoperative (Read more...)